<DOC>
	<DOCNO>NCT03092986</DOCNO>
	<brief_summary>Lung cancer lead malignancy worldwide Bangladesh . Most lung cancer Non-small Cell Lung Cancer ( NSCLC ) type . For locally advanced NSCLC , combine modality treatment require . Concurrent chemo-radiotherapy sequential chemo-radiotherapy two recommend option . Sequential chemo-radiotherapy mainly practice Bangladesh due less toxicity profile . There head head comparative study do focus sequential chemotherapy regimen use locally advanced NSCLC . Hypothesis : Null Hypothesis ( H0 ) : Sequential chemotherapy cisplatin vinblastine follow radiotherapy paclitaxel carboplatin follow radiotherapy locally advanced NSCLC , difference loco-regional tumor control . Alternative Hypothesis ( HA ) : Sequential chemotherapy cisplatin vinblastine follow radiotherapy paclitaxel carboplatin follow radiotherapy locally advanced NSCLC , cisplatin vinblastine responsive effective loco-regional tumor control paclitaxel carboplatin .</brief_summary>
	<brief_title>Outcome Cisplatin Vinblastine Versus Paclitaxel Carboplatin Sequential Chemotherapy Followed Radiotherapy Locally Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description>Lung cancer lead malignancy worldwide Bangladesh . Most lung cancer Non-small Cell Lung Cancer ( NSCLC ) type . For locally advanced NSCLC , combine modality treatment require . Concurrent chemo-radiotherapy sequential chemo-radiotherapy two recommend option . Sequential chemo-radiotherapy mainly practice Bangladesh due less toxicity profile . There head head comparative study do focus sequential chemotherapy regimen use locally advanced NSCLC . Aim Objective : To compare treatment outcome acute toxicity two standard sequential chemotherapy regimen ( Cisplatin Vinblastine follow radiotherapy Paclitaxel Carboplatin follow radiotherapy ) patient locally advanced stage III NSCLC . Material Method : A total number 60 patient , clinically locally advanced ( stage III A III B ) , histologically proven NSCLC , inoperable ECOG performance score upto grade 2 body weight loss &lt; 10 % 3 month include study . Patients randomly assign receive either Arm A Arm B . Arm A receive - paclitaxel 200 mg/m2 body surface area ( BSA ) i.v 3 hrs D1 ; carboplatin Area Under Curve ( AUC ) 6 i.v 60 minute D1 every 3 wks 2 cycle follow radiotherapy 6000 ( Centigray ) c Gy give 30 fraction begin day 42 And Arm B receive - cisplatin ( 100 mg/m2 BSA i.v 2 hr . day 1 29 ) vinblastine ( 5 mg/m2 BSA i.v rapidly push weekly day 1,8,15,22 29 ) follow radiotherapy 6000 cGy give 30 fraction begin day 50 . All patient follow per guideline 6 month study . Discussion : All relevant data compile master chart first statistical analysis result obtain use Window base computer software devise Statistical Packages Social Sciences ( SPSS-17 ) ( SPSS Inc , Chicago Illinois ( IL ) USA ) . The data analyze use Chi-square test 'T ' test association analyze Pearson 's correlation coefficient ( r value ) test . The result present table , figure , diagram . Significant value ' p ' decide level 0.05 two tailed test . Selection patient : A . Inclusion Criteria : - Patients locally advance ( stage III , b ) NSCLC . - Patients inoperable . Patients Eastern Co-operative Group ( ECOG ) performance score grade 2 . B. Exclusion Criteria : - Age 18 year . - Patients history prior chemotherapy radiotherapy lung region . - Serious concomitant medical illness include severe heart disease , uncontrolled diabetes mellitus hypertension . - Life expectancy &lt; 6 month . - Patient uncontrolled infection - Pregnant lactate woman . - Psychiatric illness . Minimum laboratory criterion require include : - Hemoglobin 10 gm . /dl 60 % . - An absolute white blood count ( WBC ) equal 4000 cells/mm3 . - Platelet count equal 100000 cells/mm3 . - Bilirubin level equal less 1.5 mg/dl . - SGPT ( serum glutamic-pyruvic transaminase ) level 4 time upper limit . - Serum creatinine level equal le 1.5 mg/dl . - Blood Urea level le 50 mg/dl . Sampling technique Randomized number generator , random number generator computational process produce random number use statistical algorithm . Outcome measure : table- clinical response , 3rd follow week 30 completion treatment arm ( n=60 ) response Arm A Arm B X2 value P value Complete response ( CR ) Partial response ( PR ) Progressive disease ( PD ) Stable disease ( SD ) Responses Description Complete Response ( CR ) Disappearance know disease , confirm ≥ 4 week Partial Response ( PR ) ≥ 50 % decrease baseline , confirm ≥ 4 week . Progressive disease ( PD ) ≥ 25 % increase one lesion appearance new lesion Stable disease ( SD ) Neither PR PD criterion meet</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>• Patients locally advance ( stage III , b ) nonsmall cell lung cancer . Patients inoperable . Patients Eastern Cooperative Group ( ECOG ) performance score grade 2 . • Age 18 year . Patients history prior chemotherapy radiotherapy lung region . Serious concomitant medical illness include severe heart disease , uncontrolled diabetes mellitus hypertension . Life expectancy &lt; 6 month . Patient uncontrolled infection Pregnant lactate woman . Psychiatric illness .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>